GlobeNewswire

VistaJet Accelerates Growth and Continues to Disrupt Business Aviation With Its Program Membership

Dela

Program Membership sales up a record 57% and customer retention hits 91%

LONDON, July 05, 2017 (GLOBE NEWSWIRE) -- VistaJet registers yet another record growth quarter, after reaching global scale with the completion of its investment plan.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bb476fcc-546a-4301-894f-103122b07f8e

For the 3 months to 30th June:

  • +51% total flight-hours sold year-on-year in Q2 2017
  • Program Membership revenue achieves record 63% of total revenue (up from 55% in the previous quarter)
  • Average aircraft utilisation rate increases by 11% compared to the preceding quarter Q1 2017

For the 6 months to 30th June:

  • Market-leading customer retention rate of 91% recorded
  • Program Membership sales up 57% year-on-year, across all regions 
  • Strong momentum to continue into the third quarter, historically VistaJet's busiest period 

VistaJet continues to gain market share in all regions around the globe in the first half of 2017 as it disrupts traditional full and fractional business aviation with its sector-leading offer, strengthening the company's reputation for a relentless focus on unparalleled customer experience, in addition to its unique business model.

VistaJet's Program Membership represented 63% of revenues in the second quarter. Growth has continued to accelerate as increasing numbers of large corporations and high-net-worth-individuals recognise the benefits of the Program's asset free solution. 37% of new hours sold in the first half of the year were generated from add-ons, compared to just 16% during the same time in 2016. Demand is being further supported by VistaJet's recent abolition of any positioning fees, a revolutionary new offer enabled by its industry leading technology investments and globally available aircraft, and one which further emphasises its commitment to transparent pricing. 

The company has also improved on its already high client retention rate, which rose to 91%, further securing its future contracted revenues. Renewal hours more than trebled in the first half of the year, with the number of new Program customers increasing by 61% compared to the same time period last year due to its focus on unique customer benefits. VistaJet now stands at 6,000 new annual subscription hours sold in H1 2017.

The US continues to represent a significant area of growth for the business. 59% of customers in this region who bought hours in 2016 have since added hours and flight hours are expected to accelerate further as the year progresses, as more and more customers discover the benefits of VistaJet's unique offer.  VistaJet growing penetration in the largest business aviation market in the world has been fuelled by positive feedback from its new customers, with many recommending VistaJet to their peers for its level of service and ground breaking business offer.

In its more mature markets, VistaJet continues to see market share gains, reinforcing its position as the operator of choice for expanding multinationals. European demand has further benefited from the overall improvement in the economic environment, and with more companies seeking to invest and explore opportunities all over the world.

This is an exciting new period of customer growth for the business. With a fleet of over 70 identical and fully owned aircraft, and a comprehensively stable cost base, VistaJet gains the benefits of the strategic investments made over the past few years and has still the capacity to nearly double its sales with its existing fleet.

Chairman and Founder Thomas Flohr said: "We have spent 13 years building up a world class fleet and unsurpassed global offering, and I want to thank everyone involved in the business for their hard work and commitment to serve our clients. Our impressive performance is the proof that customers have embraced our unique model. We look forward to continuing to shake up the business aviation industry to offer our customers the true alternative to full and fractional aircraft ownership without compromise."

About VistaJet 

VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com

Information

Jennifer Tyler
VistaJet International
T: +44 203 617 3077
M: +44 7834 335505
jennifer.tyler@vistajet.com

James Leviton
Finsbury
T: +44 207 251 3851
VistaJet@finsbury.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum